LAG3 and renal cell carcinoma: These findings suggest that LAG3 may serve as a key mechanism of immune resistance in RCC and highlight the potential therapeutic benefit of dual PD-1/LAG3 blockade, particularly in tumors with elevated LAG3 expression or tumors unresponsive to existing immunotherapies.